BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis

Endocrine-Related Cancer

Volumn 22, Issue 2, 2015, Pages 159-168

  Li, Fei ^a,b,c   Chen, Guangqi ^a   Sheng, Chunjun ^a   Gusdon, Aaron M ^d   Huang, Yueye ^a   Lv, Zhongwei ^e,f   Xu, Huixiong ^e,f   Xing, Mingzhao ^f,g   Qu, Shen ^a,b,f  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^f TONGJI UNIVERSITY   (China)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAFV600E mutation; Meta analysis; Papillary thyroid microcarcinoma; Prognosis; Thyroid cancer

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL FEATURE; COCHRANE LIBRARY; COMPARATIVE STUDY; DISEASE ASSOCIATION; EMBASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MANAGED CARE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PAPILLARY THYROID MICROCARCINOMA; PATIENT RISK; PREVALENCE; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THYROID CARCINOMA; CARCINOMA, PAPILLARY; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PATHOLOGY; THYROID NEOPLASMS;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84929310294     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0531     Document Type: Article

References (52)

1. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A et al. 2010 Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. Journal of Clinical Endocrinology and Metabolism 95 4197-4205. (doi:10.1210/jc.2010-0337)
2. de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A et al. 2014 High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E1530-E1538. (doi:10.1210/jc.2013-4389)
3. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC & Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 504-515. (doi:10.1210/jc.2007-1154)
4. V600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World Journal of Surgical Oncology 11 291. (doi:10.1186/1477-7819-11-291)
5. Chung SY, Lee JS, Lee H, Park SH, Kim SJ & Ryu HS 2013 Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma. Acta Cytologica 57 252-258. (doi:10.1159/000343617)
6. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
7. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954. (doi:10.1038/nature00766)
9. V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Journal of Clinical Endocrinology and Metabolism 97 4390-4398. (doi:10.1210/jc.2012-1775)
10. V600E mutation and the biology. Endocrine-Related Cancer 15 191-205. (doi:10.1677/ERC-07-0212)
11. V600Ealleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 97 2333-2340. (doi:10.1210/jc.2011-3106)
12. V600E is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 517-524. (doi:10.1210/jc.2011-0618)
13. Higgins JP, Thompson SG, Deeks JJ & Altman DG 2003 Measuring inconsistency in meta-analyses. BMJ 327 557-560. (doi:10.1136/bmj.327.7414.557)
14. Hughes DT, Haymart MR, Miller BS, Gauger PG & Doherty GM 2011 The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 21 231-236. (doi:10.1089/thy.2010.0137)
15. Ito Y & Miyauchi A 2007 A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nature Clinical Practice. Endocrinology & Metabolism 3 240-248. (doi:10.1038/ncpendmet0428)
16. Ito Y & Miyauchi A 2009 Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocrine Journal 56 177-192. (doi:10.1507/endocrj.K08E-166)
17. Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M & Koo BS 2012 Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Journal of Clinical Endocrinology and Metabolism 97 3996-4003. (doi:10.1210/jc.2012-2444)
18. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ & Lee KY 2010 Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Modern Pathology 23 1201-1208. (doi:10.1038/modpathol.2010.116)
19. V600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63 588-593. (doi:10.1111/j.1365-2265.2005.02389.x)
20. V600Emutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118 1764-1773. (doi:10.1002/cncr.26500)
21. V600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42 404-410. (doi:10.1007/s12020-012-9651-x)
22. V600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253 854-860. (doi:10.1148/radiol.2533090471)
23. V600E mutational status in high aggressive papillary thyroid microcarcinoma. Annals of Surgical Oncology 16 240-245. (doi:10.1245/s10434-008-0233-3)
24. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ & Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Annals of Surgical Oncology 17 3294-3300. (doi:10.1245/s10434-010-1129-6)
25. Liu D, Liu Z, Condouris S & Xing M 2007 BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 92 2264-2271. (doi:10.1210/jc.2006-1613)
26. LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simo{combining double acute accent}es M, Wenig B. 2004 Papillary carcinoma. In: Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours, vol 8, pp 57-66. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon, France: IARC Press.
27. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P et al. 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 4085-4090. (doi:10.1210/jc.2007-1179)
28. V600E mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 22 292-298. (doi:10.1089/thy.2011.0107)
29. Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Kitano M, Khanafshar E, Ljung BM, Duh QY, Clark OH et al. 2010 A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery 148 1170-1176 discussion 1176-1177. (doi:10.1016/j.surg.2010.09.025)
30. Min HS, Choe G, Kim SW, Park YJ, Park do J, Youn YK, Park SH, Cho BY &Park SY 2008 S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Modern Pathology 21 748-755. (doi:10.1038/modpathol.2008.51)
31. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH & Kebebew E 2010 Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World Journal of Surgery 34 2589-2594. (doi:10.1007/s00268-010-0720-0)
32. V600Emutation status. Histopathology 63 726-734. (doi:10.1111/his.12233)
33. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W &European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 154 787-803. (doi:10.1530/eje.1.02158)
34. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (Eds) 2007 SEER Cancer Statistics Review, 1975-2004 (based on the November 2006 SEER data submission, posted to the SEER web site 2007), available at: http://seer.cancer.gov/csr/1975-2004/ [accessed June 1, 2010].
35. kip1 expression in papillary carcinomas of the thyroid
36. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J et al. 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19 1043-1048. (doi:10.1089/thy.2008.0407)
37. Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM & Fadda G 2013 BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathology 121 291-297. (doi:10.1002/cncy.21258)
38. Roti E, degli Uberti EC, Bondanelli M & Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. European Journal of Endocrinology 159 659-673. (doi:10.1530/EJE-07-0896)
39. Schulten HJ, Salama S, Al-Mansouri Z, Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H, Al-Johari A, Huwait E et al. 2012 BRAF mutations in thyroid tumors from an ethnically diverse group. Hereditary Cancer in Clinical Practice 10 10. (doi:10.1186/1897-4287-10-10)
40. Tufano RP, Teixeira GV, Bishop J, Carson KA & Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 91 274-286. (doi:10.1097/MD.0b013e31826a9c71)
41. V600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Modern Pathology 26 62-70. (doi:10.1038/modpathol.2012.152)
42. Witt RL 2008 Initial surgical management of thyroid cancer. Surgical Oncology Clinics of North America 17 71-91 viii. (doi:10.1016/j.soc.2007.10.010)
43. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262. (doi:10.1677/erc.1.0978)
44. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
45. Xing M 2009 BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Annals of Surgical Oncology 16 801-803. (doi:10.1245/s10434-008-0298-z)
46. Xing M 2013 Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews. Cancer 13 184-199. (doi:10.1038/nrc3431)
47. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379. (doi:10.1210/jc.2005-0987)
48. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M et al. 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. Journal of Clinical Oncology 27 2977-2982. (doi:10.1200/JCO.2008.20.1426)
49. Xing M, Haugen BR & Schlumberger M 2013a Progress in molecular-based management of differentiated thyroid cancer. Lancet 381 1058-1069. (doi:10.1016/S0140-6736(13)60109-9)
50. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. 2013b Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 309 1493-1501. (doi:10.1001/jama.2013.3190)
51. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlova B, Yip L, Mian C et al. 2014 Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. Journal of Clinical Oncology 33 42-50. (doi:10.1200/JCO.2014.56.8253)
52. V600Emutational status of 977 cases. Annals of Surgical Oncology 20 2266-2273. (doi:10.1245/s10434-012-2851-z)